#cafepharma — Public Fediverse posts

Merck claims late-stage study success for RSV antibody  — Novo Nordisk's Wegovy gets UK approval for lowering heart risks — J&J vets burst into biotech with $165M Third Arc series A —http://bit.ly/w28kSd #rsv #merck #novonordisk #uk #wegovy #funding #jnj #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Merck claims late-stage study success for RSV antibody  — Novo Nordisk's Wegovy gets UK approval for lowering heart risks — J&J vets burst into biotech with $165M Third Arc series A —http://bit.ly/w28kSd #rsv #merck #novonordisk #uk #wegovy #funding #jnj #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Merck claims late-stage study success for RSV antibody  — Novo Nordisk's Wegovy gets UK approval for lowering heart risks — J&J vets burst into biotech with $165M Third Arc series A —http://bit.ly/w28kSd #rsv #merck #novonordisk #uk #wegovy #funding #jnj #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Merck claims late-stage study success for RSV antibody  — Novo Nordisk's Wegovy gets UK approval for lowering heart risks — J&J vets burst into biotech with $165M Third Arc series A —http://bit.ly/w28kSd #rsv #merck #novonordisk #uk #wegovy #funding #jnj #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Moderna receives $176 million from BARDA for mRNA influenza vaccines—J&J, Legend's Carvykti shows CAR-T can extend lives in multiple myeloma —The IRA will lower U.S. drug spending, CMS finds — but not for awhile—http://bit.ly/w28kSd #moderna #barda #mrna #vaccines #flu #jnj #multiplemyeloma #ira #drugspending #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Moderna receives $176 million from BARDA for mRNA influenza vaccines—J&J, Legend's Carvykti shows CAR-T can extend lives in multiple myeloma —The IRA will lower U.S. drug spending, CMS finds — but not for awhile—http://bit.ly/w28kSd #moderna #barda #mrna #vaccines #flu #jnj #multiplemyeloma #ira #drugspending #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Moderna receives $176 million from BARDA for mRNA influenza vaccines—J&J, Legend's Carvykti shows CAR-T can extend lives in multiple myeloma —The IRA will lower U.S. drug spending, CMS finds — but not for awhile—http://bit.ly/w28kSd #moderna #barda #mrna #vaccines #flu #jnj #multiplemyeloma #ira #drugspending #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Moderna receives $176 million from BARDA for mRNA influenza vaccines—J&J, Legend's Carvykti shows CAR-T can extend lives in multiple myeloma —The IRA will lower U.S. drug spending, CMS finds — but not for awhile—http://bit.ly/w28kSd #moderna #barda #mrna #vaccines #flu #jnj #multiplemyeloma #ira #drugspending #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

GLP-1 global obesity market to reach $111B by 2033, despite headwinds—Takeda circles leukemia rival to Novartis' Scemblix in up to $1.3B deal with Ascentage —J.P. Morgan's private financing arm closes inaugural $500M-plus biotech fund—http://bit.ly/w28kSd #obesity #glp1 #novonordisk #elililly #novartis #takeda #vml #funding #jpmorgan #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

GLP-1 global obesity market to reach $111B by 2033, despite headwinds—Takeda circles leukemia rival to Novartis' Scemblix in up to $1.3B deal with Ascentage —J.P. Morgan's private financing arm closes inaugural $500M-plus biotech fund—http://bit.ly/w28kSd #obesity #glp1 #novonordisk #elililly #novartis #takeda #vml #funding #jpmorgan #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

GLP-1 global obesity market to reach $111B by 2033, despite headwinds—Takeda circles leukemia rival to Novartis' Scemblix in up to $1.3B deal with Ascentage —J.P. Morgan's private financing arm closes inaugural $500M-plus biotech fund—http://bit.ly/w28kSd #obesity #glp1 #novonordisk #elililly #novartis #takeda #vml #funding #jpmorgan #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

GLP-1 global obesity market to reach $111B by 2033, despite headwinds—Takeda circles leukemia rival to Novartis' Scemblix in up to $1.3B deal with Ascentage —J.P. Morgan's private financing arm closes inaugural $500M-plus biotech fund—http://bit.ly/w28kSd #obesity #glp1 #novonordisk #elililly #novartis #takeda #vml #funding #jpmorgan #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Merck’s potential $3B EyeBio acquisition puts drugmaker back in ophthalmology—J&J's depression treatment succeeds in late-stage study — AstraZeneca throws its hat into the oral PCSK9 ring--http://bit.ly/w28kSd #merck #mergersandacquistions #clinicaltrials #ophthalmology #depression #jnj #astrazeneca #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Merck’s potential $3B EyeBio acquisition puts drugmaker back in ophthalmology—J&J's depression treatment succeeds in late-stage study — AstraZeneca throws its hat into the oral PCSK9 ring--http://bit.ly/w28kSd #merck #mergersandacquistions #clinicaltrials #ophthalmology #depression #jnj #astrazeneca #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Merck’s potential $3B EyeBio acquisition puts drugmaker back in ophthalmology—J&J's depression treatment succeeds in late-stage study — AstraZeneca throws its hat into the oral PCSK9 ring--http://bit.ly/w28kSd #merck #mergersandacquistions #clinicaltrials #ophthalmology #depression #jnj #astrazeneca #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Merck’s potential $3B EyeBio acquisition puts drugmaker back in ophthalmology—J&J's depression treatment succeeds in late-stage study — AstraZeneca throws its hat into the oral PCSK9 ring--http://bit.ly/w28kSd #merck #mergersandacquistions #clinicaltrials #ophthalmology #depression #jnj #astrazeneca #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J scoops up another atopic dermatitis antibody in $1.25B Numab rights deal—Health and biotech startups now get the majority of US Series A funding — Clinical-stage cancer biotech Actuate latest to eye summer IPO --http://bit.ly/w28kSd #jnj #atopicdermatitis #eczema #funding #ipos #oncology #cancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J scoops up another atopic dermatitis antibody in $1.25B Numab rights deal—Health and biotech startups now get the majority of US Series A funding — Clinical-stage cancer biotech Actuate latest to eye summer IPO --http://bit.ly/w28kSd #jnj #atopicdermatitis #eczema #funding #ipos #oncology #cancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J scoops up another atopic dermatitis antibody in $1.25B Numab rights deal—Health and biotech startups now get the majority of US Series A funding — Clinical-stage cancer biotech Actuate latest to eye summer IPO --http://bit.ly/w28kSd #jnj #atopicdermatitis #eczema #funding #ipos #oncology #cancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J scoops up another atopic dermatitis antibody in $1.25B Numab rights deal—Health and biotech startups now get the majority of US Series A funding — Clinical-stage cancer biotech Actuate latest to eye summer IPO --http://bit.ly/w28kSd #jnj #atopicdermatitis #eczema #funding #ipos #oncology #cancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J to buy Proteologix and its dual-targeting antibody drugs for $850M—Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data —FDA approves expanded use of Bristol Myers' cancer cell therapy --http://bit.ly/w28kSd #jnj #biogen #als #celltherapy #fda #bristolmyerssquibb #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J to buy Proteologix and its dual-targeting antibody drugs for $850M—Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data —FDA approves expanded use of Bristol Myers' cancer cell therapy --http://bit.ly/w28kSd #jnj #biogen #als #celltherapy #fda #bristolmyerssquibb #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J to buy Proteologix and its dual-targeting antibody drugs for $850M—Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data —FDA approves expanded use of Bristol Myers' cancer cell therapy --http://bit.ly/w28kSd #jnj #biogen #als #celltherapy #fda #bristolmyerssquibb #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J to buy Proteologix and its dual-targeting antibody drugs for $850M—Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data —FDA approves expanded use of Bristol Myers' cancer cell therapy --http://bit.ly/w28kSd #jnj #biogen #als #celltherapy #fda #bristolmyerssquibb #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J narrowly misses Q1 revenue on lower-than-expected Stelara sales—Humira biosimilar scripts take off—Intra-Cellular launches 26% to record high, breaking out after depression drug scores big--http://bit.ly/w28kSd #earnings #jnj #abbvie #humira #biosimilars #depression #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J narrowly misses Q1 revenue on lower-than-expected Stelara sales—Humira biosimilar scripts take off—Intra-Cellular launches 26% to record high, breaking out after depression drug scores big--http://bit.ly/w28kSd #earnings #jnj #abbvie #humira #biosimilars #depression #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J narrowly misses Q1 revenue on lower-than-expected Stelara sales—Humira biosimilar scripts take off—Intra-Cellular launches 26% to record high, breaking out after depression drug scores big--http://bit.ly/w28kSd #earnings #jnj #abbvie #humira #biosimilars #depression #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J scoops up cardio medtech Shockwave Medical for $13.1B—FDA allows expanded use of Bristol Myers' cell therapy for blood cancer—Boehringer to lay off salespeople as Humira biosimilar sales lag--http://bit.ly/w28kSd #jnj #shockwavemedical #fda #mergersandacquisitions #celltherapy #bloodcancer #bristolmyerssquibb #humira #boehringer #layoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J scoops up cardio medtech Shockwave Medical for $13.1B—FDA allows expanded use of Bristol Myers' cell therapy for blood cancer—Boehringer to lay off salespeople as Humira biosimilar sales lag--http://bit.ly/w28kSd #jnj #shockwavemedical #fda #mergersandacquisitions #celltherapy #bloodcancer #bristolmyerssquibb #humira #boehringer #layoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J scoops up cardio medtech Shockwave Medical for $13.1B—FDA allows expanded use of Bristol Myers' cell therapy for blood cancer—Boehringer to lay off salespeople as Humira biosimilar sales lag--http://bit.ly/w28kSd #jnj #shockwavemedical #fda #mergersandacquisitions #celltherapy #bloodcancer #bristolmyerssquibb #humira #boehringer #layoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Biogen and Eisai fall behind on Leqembi’s subcutaneous BLA for Alzheimer’s—Teva, Viatris win new chance to challenge J&J schizophrenia drug patent—3M spins out Solventum--http://bit.ly/w28kSd #biogen #eisai #alzehimers #teva #jnj #patents #schizophrenia #3m #spinoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Bayer’s oncology business looks to collect $10B in sales by 2030 — Some experts say FDA made the right call on Lilly's donanemab — Promising IPF treatment results sent Pliant Therapeutics stock soaring -- See more on our front page news http://bit.ly/w28kSd #bayer #oncology #prostatecancer #fda #elililly #donanemab #alzheimers #ipf #pharmanews #pharma #biotech #biotechnology #biopharma #cafepharma